All In Biotech

Drug Trial Radar · NCT06343311

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

Jun 1, 2024

Primary completion

Jul 31, 2027

Study completion Jul 31, 2028

Sponsor

Lead sponsor
Estrella Immunopharma, Inc.Industry
Sponsor type
Industry
Collaborators
Eureka Therapeutics Inc.
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.

Conditions

  • B-Cell Non-Hodgkin's Lymphoma (NHL)
  • Lymphoma, Non-Hodgkins
  • Lymphomas Non-Hodgkin's B-Cell
  • Non-Hodgkin Lymphoma
  • Non-Hodgkin's Lymphoma
  • Large B-Cell Lymphoma
  • Lymphoma, Non-Hodgkin's, Adult
  • Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • Lymphoma, Non-Hodgkin
  • HIV Associated Lymphoma
  • CNS Lymphoma
  • High-grade B-cell Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

  • EB103Biological

    EB103 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the EB103 transgene.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of EB103.Time frame: Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years
  2. To determine the Recommended Phase II Dose (RP2D) of EB103 (in Phase 1, Dose Escalation)Time frame: Time Frame: 16 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Davis

    Sacramento, California · Recruiting

  • University Hospitals Seidman Cancer Center

    Cleveland, Ohio · Recruiting

  • Oregon Health and Sciences University

    Portland, Oregon · Recruiting

  • Baylor Scott & White Research Institute, Texas Oncology

    Dallas, Texas · Recruiting

  • Intermountain Health, Canyons Region, LDS Hospital

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.